Arrowhead Pharmaceuticals, Inc. $ARWR Position Increased by King Luther Capital Management Corp

King Luther Capital Management Corp raised its stake in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) by 54.7% during the 3rd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 80,640 shares of the biotechnology company’s stock after buying an additional 28,500 shares during the period. King Luther Capital Management Corp’s holdings in Arrowhead Pharmaceuticals were worth $2,781,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds also recently modified their holdings of the company. Virtus Advisers LLC acquired a new position in shares of Arrowhead Pharmaceuticals in the 2nd quarter worth $34,000. Salomon & Ludwin LLC acquired a new position in shares of Arrowhead Pharmaceuticals in the 3rd quarter valued at $34,000. Nisa Investment Advisors LLC increased its stake in Arrowhead Pharmaceuticals by 75.9% in the 2nd quarter. Nisa Investment Advisors LLC now owns 3,032 shares of the biotechnology company’s stock worth $48,000 after purchasing an additional 1,308 shares in the last quarter. Federated Hermes Inc. acquired a new stake in Arrowhead Pharmaceuticals during the 3rd quarter worth about $52,000. Finally, Smartleaf Asset Management LLC raised its holdings in Arrowhead Pharmaceuticals by 2,186.5% during the 3rd quarter. Smartleaf Asset Management LLC now owns 1,692 shares of the biotechnology company’s stock worth $57,000 after buying an additional 1,618 shares during the period. Institutional investors and hedge funds own 62.61% of the company’s stock.

Arrowhead Pharmaceuticals Stock Down 0.4%

Arrowhead Pharmaceuticals stock opened at $63.59 on Friday. Arrowhead Pharmaceuticals, Inc. has a twelve month low of $9.57 and a twelve month high of $76.76. The company has a debt-to-equity ratio of 0.29, a quick ratio of 3.38 and a current ratio of 3.38. The firm has a market cap of $8.90 billion, a PE ratio of 41.56 and a beta of 1.21. The firm’s 50 day moving average price is $66.47 and its two-hundred day moving average price is $46.72.

Arrowhead Pharmaceuticals (NASDAQ:ARWR) last issued its earnings results on Thursday, February 5th. The biotechnology company reported $0.22 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.60 by ($0.38). Arrowhead Pharmaceuticals had a net margin of 18.54% and a return on equity of 35.64%. The company had revenue of $264.03 million for the quarter, compared to analyst estimates of $225.66 million. During the same period last year, the business earned ($1.39) EPS. The company’s quarterly revenue was up 10461.3% on a year-over-year basis. On average, research analysts predict that Arrowhead Pharmaceuticals, Inc. will post -2.42 EPS for the current fiscal year.

Analyst Ratings Changes

Several brokerages have commented on ARWR. Chardan Capital raised their target price on shares of Arrowhead Pharmaceuticals from $60.00 to $80.00 and gave the stock a “buy” rating in a report on Wednesday, January 7th. The Goldman Sachs Group raised their price objective on shares of Arrowhead Pharmaceuticals from $50.00 to $85.00 and gave the stock a “neutral” rating in a research note on Wednesday, January 7th. B. Riley Financial boosted their target price on shares of Arrowhead Pharmaceuticals from $61.00 to $101.00 and gave the company a “buy” rating in a research note on Thursday, January 22nd. HC Wainwright restated a “buy” rating and issued a $100.00 target price on shares of Arrowhead Pharmaceuticals in a report on Tuesday, February 10th. Finally, Piper Sandler reiterated an “overweight” rating and set a $110.00 price target (up previously from $100.00) on shares of Arrowhead Pharmaceuticals in a report on Tuesday, January 13th. One analyst has rated the stock with a Strong Buy rating, six have given a Buy rating and four have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $81.67.

Insider Activity

In other news, insider James C. Hamilton sold 40,164 shares of Arrowhead Pharmaceuticals stock in a transaction dated Monday, January 5th. The stock was sold at an average price of $63.11, for a total transaction of $2,534,750.04. Following the completion of the sale, the insider directly owned 171,958 shares in the company, valued at $10,852,269.38. The trade was a 18.93% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, COO Patrick O’brien sold 49,493 shares of the business’s stock in a transaction that occurred on Monday, January 5th. The shares were sold at an average price of $63.11, for a total value of $3,123,503.23. Following the completion of the sale, the chief operating officer directly owned 474,908 shares of the company’s stock, valued at approximately $29,971,443.88. The trade was a 9.44% decrease in their position. The SEC filing for this sale provides additional information. In the last quarter, insiders have sold 510,836 shares of company stock valued at $33,603,060. 3.60% of the stock is currently owned by company insiders.

About Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Since its founding in 2008, Arrowhead has leveraged its proprietary delivery platform—known internally as the Advanced RNAi Compound (ARC) technology—to silence disease-causing genes in patients suffering from genetically defined diseases. The company’s approach aims to offer durable, targeted treatments across a range of therapeutic areas.

The company’s pipeline includes multiple candidates in various stages of development.